2个队列患者在治疗结束后2周内LVEF均恢复到基线水平,这与CK-274的1期研究中健康受试者LVEF下降的可逆性相似。 2020年12月,中国国家药品监督管理局(NMPA)药品审评中心(CDE)网站公示,由Cytokinetics和箕星药业联合申报的一款1类新药CK-3773274(CK-274)片获得临床试验默示许可,拟开发用于梗阻性肥厚型心肌病(oHCM)。
箕星药业宣布,其治疗症状性梗阻性肥厚型心肌病(oHCM)的aficamten(CK-3773274片)3期临床试验的中国队列已于近日在首都医科大学附属北京安贞医院完成首例患者入组。 该实验目前在全国16家医院展开,旨在评价aficamten治疗oHCM的疗效和平安性,为产品(http://www.maoyihang.com/invest/)在中国的上市申请提供根据。该中...
SOUTH SAN FRANCISCO, Calif.,April 12, 2021(GLOBE NEWSWIRE) --Cytokinetics, Incorporated(Nasdaq: CYTK) today announced that data related to the optimization of CK-3773274 (CK-274), including the first disclosure of its chemical structure, were presented at theAmerican Chemical SocietySpring...
SOUTH SAN FRANCISCO, Calif. , Nov. 16, 2020 ( ) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that preclinical data for CK-3773274 (CK-274) and CK-3772271 (CK-271) were shared in poster presentations at the American Heart Association (AHA) Scientific ...